- Home
- TROX vs KROS Comparison
TROX vs KROS Comparison
Compare TROX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROX
- KROS
- Stock Information
- Founded
- TROX 2018
- KROS 2015
- Country
- TROX United States
- KROS United States
- Employees
- TROX N/A
- KROS N/A
- Industry
- TROX Major Chemicals
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- TROX Industrials
- KROS Health Care
- Exchange
- TROX Nasdaq
- KROS Nasdaq
- Market Cap
- TROX 640.4M
- KROS 565.0M
- IPO Year
- TROX 2005
- KROS 2020
- Fundamental
- Price
- TROX $3.18
- KROS $15.51
- Analyst Decision
- TROX Hold
- KROS Buy
- Analyst Count
- TROX 8
- KROS 14
- Target Price
- TROX $4.56
- KROS $20.56
- AVG Volume (30 Days)
- TROX 3.8M
- KROS 1.1M
- Earning Date
- TROX 11-05-2025
- KROS 11-06-2025
- Dividend Yield
- TROX 6.04%
- KROS N/A
- EPS Growth
- TROX N/A
- KROS N/A
- EPS
- TROX N/A
- KROS 0.47
- Revenue
- TROX $2,949,000,000.00
- KROS $232,844,000.00
- Revenue This Year
- TROX N/A
- KROS $6,657.47
- Revenue Next Year
- TROX $3.07
- KROS N/A
- P/E Ratio
- TROX N/A
- KROS $32.70
- Revenue Growth
- TROX 0.24
- KROS 85820.30
- 52 Week Low
- TROX $2.95
- KROS $9.12
- 52 Week High
- TROX $13.14
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- TROX 34.81
- KROS 54.40
- Support Level
- TROX $3.68
- KROS $14.86
- Resistance Level
- TROX $3.91
- KROS $15.30
- Average True Range (ATR)
- TROX 0.20
- KROS 0.62
- MACD
- TROX -0.03
- KROS 0.05
- Stochastic Oscillator
- TROX 5.92
- KROS 90.49
About TROX Tronox Holdings plc (UK)
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.